{
  "hash": "39fba036687c700a8cc38c9d44bafcb1",
  "result": {
    "markdown": "---\ntitle: \"\"\ndate: last-modified\nexecute:   \n  freeze: auto  # re-render only when source changes\noutput: \n  rmarkdown::html_document:\n    highlight: pygments\n    number_sections: yes\n    self_contained: yes\n    toc: yes\n    toc_depth: 2\n    toc_float: yes\ntbl-colwidths: [5,41,42,12]\n---\n\n\n\n\n# Recordings\n\nRecordings of those sessions where all presenters have given consent (Sessions 5 might be added later, pending speaker consent):\n\n\n\n\n::: {.cell}\n::: {.cell-output-display}\n|Number |Session                                                                                                                     |   |Link<br>(if available) |\n|:------|:---------------------------------------------------------------------------------------------------------------------------|:--|:----------------------|\n|1      |Regulatory and HTA update                                                                                                   |   |[x](https://youtu.be/-ptm6gdB1_w)|\n|2      |Synthetic and other baseline covariates: The promise of smaller and faster clinical trials through prognostic digital twins |   |[x](https://youtu.be/WW5P_tMTt08)|\n|3      |Complex innovative trials for regulatory decision-making                                                                    |   |[x](https://youtu.be/ogjgdsbg2ow)|\n|4      |How to get most out of Scientific Advice                                                                                    |   |[x](https://youtu.be/ANJO2RB3q0A)|\n|5      |Use of non-RCT studies in regulatory decision-making                                                                        |   |[x](https://youtu.be/Bx1eKDW-gcs)|\n|6      |Short Topics                                                                                                                |   |[x](https://youtu.be/tW9VyesW7h8)|\n:::\n:::\n\n\n# Material\n\n\n\n\n::: {.cell}\n\n:::\n\n## Opening {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|Talk |Speaker and affiliation                                |Talk title      |Download<br>(if available) |\n|:----|:------------------------------------------------------|:---------------|:--------------------------|\n|1    |Justine Rochon (Boehringer Ingelheim, EFSPI president) |Opening remarks |[x](slides/01_Rochon.pdf)  |\n:::\n:::\n\n::: {.cell}\n\n:::\n\n## Session 1: Regulatory and HTA update {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|Talk |Speaker and affiliation                                                                                       |Talk title                                                               |Download<br>(if available) |\n|:----|:-------------------------------------------------------------------------------------------------------------|:------------------------------------------------------------------------|:--------------------------|\n|1    |Kristin Karlsson (Swedish Medical Products Agency, Uppsala University, EMA, Vice-chair MWP)                   |EMA Methodology Working Party update                                     |[x](slides/11_Karlsson.pdf)|\n|2    |Eftychia-Eirini Psarelli (University of Liverpool, EMA)                                                       |EMA update on submission of individual patient data from clinical trials |[x](slides/12_Psarelli.pdf)|\n|3    |David McConnell (Statistician National Centre for Pharmacoeconomics, Ireland, Methodology Subgroup of HTA CG) |Update on joint HTA work under the EU HTA Regulation                     |[x](slides/13_McConnell.pdf)|\n:::\n:::\n\n::: {.cell}\n\n:::\n\n## Short topics {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|Talk |Speaker and affiliation                                                                                                 |Talk title                                                                                    |Download<br>(if available) |\n|:----|:-----------------------------------------------------------------------------------------------------------------------|:---------------------------------------------------------------------------------------------|:--------------------------|\n|1    |Fredrik Öhrn (Janssen)                                                                                                  |Formal statistical requirements for a pivotal trial to support approval of a combination drug |[x](slides/st1_Oehrn.pdf)  |\n|2    |Betty Molloy (Novartis)                                                                                                 |Use of RWE in drug labelling                                                                  |[x](slides/st2_Molloy.pdf) |\n|3    |Patrick Schloemer (Bayer)                                                                                               |Hierarchical Composite Endpoints for Chronic Kidney Disease Trials                            |[x](slides/st3_Schloemer.pdf)|\n|4    |Simon Wandel (Novartis)                                                                                                 |What’s the rule for the pool?                                                                 |[x](slides/st4_Wandel.pdf) |\n|5    |Sandro Gsteiger (Roche) and Anders Gorst-Rasmussen (Novo Nordisk on behalf of the PSI/EFSPI HTA Special Interest Group) |Surrogate endpoints - can EMA and EU HTA align on common standards?                           |[x](slides/st5_Gsteiger.pdf)|\n|6    |Susan Robson (Roche)                                                                                                    |Data Quality issues in IITs                                                                   |[x](slides/st6_Robson.pdf) |\n:::\n:::\n\n::: {.cell}\n\n:::\n\n## Session 2: Synthetic and other baseline covariates: The promise of smaller and faster clinical trials through prognostic digital twins {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|Talk |Speaker and affiliation              |Talk title                                                                               |Download<br>(if available) |\n|:----|:------------------------------------|:----------------------------------------------------------------------------------------|:--------------------------|\n|1    |Andreas Brandt (BfArM, EMA)          |Covariate Adjustment: Traditional principles and challenges by new approaches            |[x](slides/21_Brandt.pdf)  |\n|2    |Courtney Schiffman (Genentech Roche) |Strategic considerations and value of covariate adjustment                               |[x](slides/22_Schiffman.pdf)|\n|3    |Daniel Rubin (FDA)                   |Adjusting for covariates in randomized clinical trials for drugs and biological products |[x](slides/23_Rubin.pdf)   |\n:::\n:::\n\n::: {.cell}\n\n:::\n\n## Session 3: Complex innovative trials for regulatory decision-making {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|Talk |Speaker and affiliation                                                                             |Talk title                                                                                                         |Download<br>(if available) |\n|:----|:---------------------------------------------------------------------------------------------------|:------------------------------------------------------------------------------------------------------------------|:--------------------------|\n|1    |Khadija Rantell (MHRA), Frank Bretz (Novartis), Hans Ulrich Burger (Roche)                          |Some guidance on when applying adaptive designs                                                                    |[x](slides/31_Rantell.pdf) |\n|2    |Wolfgang Jacquet (Vrije Universiteit Brussel, EMA) and Benjamin Hofner (Paul-Ehrlich Institut, EMA) |Platform trials in a confirmatory regulatory setting – generating thoughts and directions                          |[x](slides/32_Jacquet.pdf) |\n|3    |Dieter Haering (Novartis)                                                                           |Experience with and learnings from regulatory interactions around innovative trial designs based on the NEOS study |[x](slides/33_Haering.pdf) |\n:::\n:::\n\n::: {.cell}\n\n:::\n\n## Session 4: How to get most out of Scientific Advice {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|Talk |Speaker and affiliation                                    |Talk title                                                                                                                                                   |Download<br>(if available) |\n|:----|:----------------------------------------------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------|\n|1    |Tommi Nurminen (fimea, EMA) and Antero Kallio (fimea, EMA) |How to efficiently leverage scientific advice - a joint statistical and clinical perspective                                                                 |[x](slides/41_Nurminen.pdf)|\n|2    |Gergő Merész (Co-Chair of the JSC Subgroup (HTA R))        |HTA Joint Scientific Consultation                                                                                                                            |[x](slides/42_Meresz.pdf)  |\n|3    |David Wright (AstraZeneca)                                 |Tips on a) what questions to ask regulators and HTAs, b) interpreting the answers given and c) what to do when different authorities give conflicting advice |[x](slides/43_Wright.pdf)  |\n:::\n:::\n\n::: {.cell}\n\n:::\n\n## Session 5: Use of non-RCT studies in regulatory decision-making {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|Talk |Speaker and affiliation              |Talk title                                                                                            |Download<br>(if available) |\n|:----|:------------------------------------|:-----------------------------------------------------------------------------------------------------|:--------------------------|\n|1    |Kit Roes (Radboud Universiteit, EMA) |Single Arm Trials: The EMA Reflection Paper                                                           |[x](slides/51_Roes.pdf)    |\n|2    |Mark Levenson (FDA)                  |United States FDA Real World Evidence Program: A Quick Tour                                           |[x](slides/52_Levenson.pdf)|\n|3    |Pallavi Mishra-Kalyani (FDA)         |Regulatory Issues with the Use of External Controls and the US FDA RWE Program                        |[x](slides/52_Mishra.pdf)  |\n|4    |Emmanuel Zuber (Novartis)            |External control for approval and labeling: Two case studies trying to figure out when it is worth it |[x](slides/53_Zuber.pdf)   |\n|4    |Stefan Lange (IQWiG)                 |HTA view on the EMA draft reflection paper and the FDA guidance                                       |[x](slides/54_Lange.pdf)   |\n:::\n:::\n\n::: {.cell}\n\n:::\n\n## Posters {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|Talk |Speaker and affiliation                                                                                      |Talk title                                                                                                                                                                               |Download<br>(if available) |\n|:----|:------------------------------------------------------------------------------------------------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------|\n|1    |EFSPI / PSI & ASA biopharmaceutical section oncology estimand working group (conditional marginal taskforce) |Conditional and Unconditional treatment effects in randomized clinical trials: trials: EstimandsEstimands, Estimation, and Interpretation, Estimation, and Interpretation                |[x](slides/p1_CondMarg.pdf)|\n|2    |EFSPI / PSI Regulatory SIG                                                                                   |Regulatory ESIG                                                                                                                                                                          |[x](slides/p2_Regulatory.pdf)|\n|3    |EFPIA / EFSPI estimand implementation working group                                                          |How the \"Estimand Implementation Working Group\" brings together statisticians and clinicians to support the estimand journeystatisticians and clinicians to support the estimand journey |[x](slides/p3_EIWG.pdf)    |\n|4    |EFSPI / PSI biomarker SIG                                                                                    |The Biomarkers European Special Interest Group: European Special Interest Group: Where are we now?Where are we now?                                                                      |[x](slides/p4_Biomarker.pdf)|\n|5    |EFSPI / PSI historical data SIG                                                                              |Beyond the classical type I error: Bayesian metrics for Bayesian designs using informative priors                                                                                        |[x](slides/p5_Historical.pdf)|\n|6    |EFSPI / PSI Launch & Lifecycle Special Interest Group                                                        |EFSPI / PSI Launch & Lifecycle Special Interest Group                                                                                                                                    |[x](slides/p6_Launch.pdf)  |\n|7    |EFSPI / PSI HTA SIG                                                                                          |EU HTA -- How can statisticians help navigate the problem of multiplicity?                                                                                                               |[x](slides/p7_HTA_multiplicity.pdf)|\n|8    |EFSPI / PSI HTA SIG                                                                                          |What's the HTA ESIG doing to prepare for EU HTA?                                                                                                                                         |[x](slides/p8_HTA_prepare_EU_HTA.pdf)|\n|9    |BBS Next Generation                                                                                          |Summary of BBS Next Generation Seminar: \"Future of the Next Generation Statisticians and Quantitative Scientists\"                                                                        |[x](slides/p9_NextGen.pdf) |\n:::\n:::\n",
    "supporting": [],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}